Testosterone replacement therapy and the risk of prostate cancer. Is there a link?

International Journal of Impotence Research

Volumn 18, Issue 4, 2006, Pages 323-328

  Barqawi, A ^a   Crawford, E D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Prostate cancer; Testosterone; Testosterone replacement therapy

Indexed keywords

ALPHA TOCOPHEROL; CAROTENE; FINASTERIDE; LYCOPENE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; RETINOL; SELENIUM; SEX HORMONE BINDING GLOBULIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TESTOSTERONE ENANTATE;

AGING; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; DISEASE ASSOCIATION; GLEASON SCORE; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; REVIEW; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

CONTINENTAL POPULATION GROUPS; GUIDELINES; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TESTOSTERONE;

EID: 33745700791     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901418     Document Type: Review

References (42)

1. Wilson JD. The Pharmacological Basis of Therapeutics. In: Hardman JG, Limbird LE (eds) Androgens 10th edn. McGraw-Hill: New York, 2001, pp. 1441-1498.
2. Han G, Buchanan G, Ittmann M, Harris JM, Yu X, Demayo FJ et al. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci USA 2005; 102: 1151-1156.
3. Soronen P, Laiti M, Torn S, Harkonen P, Patrikainen L, Li Y et al. Sex steroid hormone metabolism and prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 281-286.
4. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 2085-2098.
5. Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004; 90: 871-876.
6. Huggins C, Hodges CV. Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-297.
7. Morales A. Androgen replacement therapy and prostate safety. Eur Urol 2002; 41: 113-120.
8. Litvinov IV, Antony L, Isaacs JT. Molecular characterization of an improved vector for evaluation of the tumor suppressor versus oncogene abilities of the androgen receptor. Prostate 2004; 61: 299-304.
9. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724-731, Notes: CORPORATE NAME: Baltimore Longitudinal Study of Aging.
10. Deslypere JP, Vermeulen A. Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metab 1984; 59: 955-962.
11. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002; 87: 589-598.
12. Roberts RO, Jacobson DJ, Rhodes T, Klee GG, Leiber MM, Jacobsen SJ. Serum sex hormones and measures of benign prostatic hyperplasia. Prostate 2004; 61: 124-131.
13. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-224.
14. Bonkhoff H, Stein U, Remberger K. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 1994; 25: 42-46.
15. Bonkhoff H, Stein U, Remberger K. The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 1994; 24: 114-118.
16. Morgentaler A, Bruning 3rd CO, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996; 276: 1904-1906.
17. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxford) 1994; 40: 341-349.
18. Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl 2002; 23: 922-926.
19. Schatzl G, Madersbacher S, Haitel A, Gsur A, Preyer M, Haidinger G et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 2003; 169: 1312-1315.
20. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003; 169: 1670-1675.
21. Imamoto T, Suzuki H, Fukasawa S, Shimbo M, Inahara M, Komiya A et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol 2005; 47: 308-312.
22. Furuya Y, Nozaki T, Nagakawa O, Fuse H. Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer. Endocr J 2002; 49: 85-90.
23. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000; 18(4): 847-853.
24. Chen C, Weiss NS, Stanczyk FZ, Lewis SK, DiTommaso D, Etzioni R et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2003; 12: 1410-1416.
25. Zagars GK, Pollack A, von Eschenbach AC. Serum testosterone - a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology 1997; 49: 327-334.
26. Mikkola AK, Aro JL, Rannikko SA, Salo JO. Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer. FINN-PROSTATE Group. Prostate 1999; 39: 175-181.
27. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986; 76: 45-48.
28. Kubricht 3rd WS, Williams BJ, Whatley T, Pinckard P, Eastham JA. Serum testosterone levels in African-American and white men undergoing prostate biopsy. Urology 1999; 54: 1035-1038.
29. Mohler JL, Gaston KE, Moore DT, Schell MJ, Cohen BL, Weaver C et al. Racial differences in prostate androgen levels in men with clinically localized prostate cancer. J Urol 2004; 171: 2277-2280.
30. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005; 90: 1502-1510.
31. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89: 503-510.
32. Yamamoto T, Ito K, Ohi M, Kubota Y, Suzuki K, Fukabori Y et al. Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 NG/ML or less. Urology 2001; 58: 994-998.
33. Potter SR, Horniger W, Tinzl M, Bartsch G, Partin AW. Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology 2001; 57: 1100-1104.
34. Philip J, Dutta Roy S, Ballal M, Foster CS, Javle P. Is a digital rectal examination necessary in the diagnosis and clinical staging of early prostate cancer? BJU Int 2005; 95: 969-971.
35. Karakiewicz PI, Benayoun S, Kattan MW, Perrotte P, Valiquette L, Scardino PT et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol 2005; 173: 1930-1934.
36. Berger AP, Deibl M, Steiner H, Bektic J, Pelzer A, Spranger R et al. Longitudinal PSA changes in men with and without prostate cancer: Assessment of prostate cancer risk. Prostate 2005; 64: 240-245.
37. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005; 173: 533-536.
38. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin N Am 2001; 28: 555-565.
39. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl 2005; 28: 125-127.
40. Stattin P, Soderberg S, Hallmans G, Bylund A, Kaaks R, Stenman UH et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab 2001; 86: 1341-1345.
41. Chen SS, Chen KK, Lin AT, Chang YH, Wu HH, Chang LS. The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int 2002; 89: 710-713.
42. Ribeiro M, Ruff P, Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 1997; 20: 605-608.